OncoGenex prices $50 million offering

OncoGenex Pharmaceuticals (NASDAQ: OGXI) has priced a public offering of 3,174,602 units at $15.75 (U.S.) per unit, with each unit consisting of one common share and one-half of a warrant. The stock closed at 18.75 on Monday. Net proceeds of about $46.7 million will be used primarily to advance the company’s product pipeline, including its [...]

OncoGenex starts prostate cancer trial

OncoGenex Pharmaceuticals (NASDAQ:OGXI) has initiated a randomized, investigator-sponsored Phase 2 trial of its OGX-427 drug candidate in men with metastatic prostate cancer. The study will enrol up to 72 men who have minimally symptomatic or asymptomatic advanced prostate cancer and who have not yet received chemotherapy. It is designed to determine the potential benefit of [...]

Canadians’ data heading to ASCO

Versant Partners analyst Doug Loe has compiled a list of six biotech companies that will have data presented at the American Society of Clinical Oncology meeting on June 4 to 8.  He expects: · AEterna Zentaris (NASDAQ:AEZS; TSX:AEZ) to report final data from its 43-patient Phase 2 advanced ovarian cancer trial with its AEZS-108 drug, [...]